What is the risk of esophageal injury for patients taking alendronate, risedronate, ibandronate, or etidronate?
Metadata[+] Show full item record
In prospective trials, use of alendronate and risedronate resulted in a rate of esophageal injury similar to that of placebo (SOR A, based on systematic reviews of RCTs). Although less evidence is available regarding etidronate and ibandronate, both appear to also have low risk of causing esophageal injury (SOR B, based on a single RCT).
Evidence Based Practice 11(1): 07-08.